Tigecycline Products Market Generated Opportunities, Future Scope 2022-2028 | Amneal Pharmaceuticals, Inc., Novartis International AG, Xellia pharmaceuticals ApS, Abbott Laboratories

Overview:

Tigecycline belongs to a class of drugs called tetracycline antibiotics, it is sold under the brand name Tygacil. It is an antibiotic, used for treating bacterial infections like gonorrhea, urinary tract infections, chlamydia and acne. This can also be used as an alternative in the treating gram negative and gram positive bacterial infections, especially for those patients allergic to penicillin or those having antimicrobial toxicities. Tigecycline prevents the bacteria from producing cell proteins that are required for growth of the bacteria by binding to the bacterial ribosomes.

Request PDF Research Report Brochure @ https://www.coherentmarketinsights.com/insight/request-pdf/4168

Impact of COVID-19:

The pandemic has affected various markets around the world. Many pharmaceutical companies are facing challenges like changes in demand, delay in approvals for generic medicines, regulatory revisions, restrictions in product exportation and disruption in supply chains due to strict lockdown policies by various governments. All these factors have affected the growth of the global tigecycline products market negatively.

Drivers:

Increasing incidences of gonorrhea in the United States of America is expected to boost the growth of the global tigecycline products market during the forecast period.  For instance, a report by the Centers for Disease Control and Prevention in 2017, mentioned that 555,608 incidences of gonorrhea have been reported in the U.S. Thus, resulting in launching of new products by pharmaceutical companies for the treatment of these bacterial infections. For instance, Sandoz Inc. launched a generic version of Tygacil injection, at a lower price, so as to make the drug affordable. This is expected to propel the growth of the global tigecycline products market during the forecast period.

Restraints:

Factors such as side effects of the drug, increase in mortality rate due to pneumonia and cost effectiveness are expected to hamper the growth of the global tigecycline products market during the forecast period.  Tigecycline is distinguished by side effects like fever, headache, difficulty in hearing, vision, cough or urination, lower back pain and side pain.

Regional Analysis:

North America is expected to witness robust growth in the global tigecycline products market during the forecast period, due to increasing incidences of chlamydia trachomtis. For instance, the Centers for Disease Control and Prevention reported around 1,598,354 cases of chlamydia trachomatis infection in 2016 and 497.3 cases in 2015. For instance, Fresenius Kabi declared the launch of Tigecycline injection, which will be available in a single dose vials and is Pfizer’s generic version of Tygacil.

Furthermore, Europe is also expected to witness growth in the global tigecycline products market during the forecast period, owing to rising incidences of gonorrhea and chlamydia. For instance, a report by the National Health Service in 2018, stated that in England 44,500 individuals under the age of 25 were diagnosed with gonorrhea in 2017. Many pharma companies are launching new products for treating bacterial infections. For instance, European Medicines Agency has given approval for marketing of tigecycline injection manufactured by Accord Healthcare, used for treating bacterial diseases.

Market Taxonomy:

On the basis of application

• Urinary Tract Infection (UTI)
• Skin and Soft Tissue Infections
• Complicated Intra-Abdominal Infections
• Community-acquired Bacterial Pneumonia
• Gonorrhea
• Chlamydia
• Others

On the basis of distribution channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

On the basis of region

• North America
• Latin America
• Europe
• Middle East
• Asia Pacific
• Africa

Get PDF Sample Copy of Report (Including Full TOC, List of Tables & Figures, Chart) @ https://www.coherentmarketinsights.com/insight/request-sample/4168

Key Players

Key players active in the global tigecycline products market are AstraZeneca plc, Amneal Pharmaceuticals Inc, Pfizer Inc., Novartis International AG, Fresenius Kabi USA LLC, Xellia pharmaceuticals ApS, Aurobindo Pharma Limited, Accord Healthcare Inc. and Apotex, Inc.

Table of Content

Chapter 1 Industry Overview
1.1 Definition
1.2 Assumptions
1.3 Research Scope
1.4 Market Analysis by Regions
1.5 Tigecycline Products Market Size Analysis from 2022 to 2028
11.6 COVID-19 Outbreak: Tigecycline Products Industry Impact

Chapter 2 Global Tigecycline Products Competition by Types, Applications, and Top Regions and Countries
2.1 Global Tigecycline Products (Volume and Value) by Type
2.3 Global Tigecycline Products (Volume and Value) by Regions

Chapter 3 Production Market Analysis
3.1 Global Production Market Analysis
3.2 Regional Production Market Analysis

Chapter 4 Global Tigecycline Products Sales, Consumption, Export, Import by Regions (2017-2022)
Chapter 5 North America Tigecycline Products Market Analysis
Chapter 6 East Asia Tigecycline Products Market Analysis
Chapter 7 Europe Tigecycline Products Market Analysis
Chapter 8 South Asia Tigecycline Products Market Analysis
Chapter 9 Southeast Asia Tigecycline Products Market Analysis
Chapter 10 Middle East Tigecycline Products Market Analysis
Chapter 11 Africa Tigecycline Products Market Analysis
Chapter 12 Oceania Tigecycline Products Market Analysis
Chapter 13 South America Tigecycline Products Market Analysis
Chapter 14 Company Profiles and Key Figures in Tigecycline Products Business
Chapter 15 Global Tigecycline Products Market Forecast (2022-2028)
Chapter 16 Conclusions
Research Methodology